ACTRN12605000742673招募中2 期
A Phase II, randomised, double-blinded, dose ranging study of AVX754 to reduce the viral load versus lamivudine in treatment experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase.
Avexa Ltd0 个研究点目标入组 60 人开始时间: 2005年11月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- ot stated 至 ot stated（—）
- 性别
- All
入选标准
- •Informed consentHIV-1 infectedM184V mutation in reverse transcriptaseCurrently taking lamivudineViral load >2,000 copies/mlCD4+ T-cell count>50 cells.
排除标准
- •Hep B surface Antigen PositivePregnant or breast feeding femalesHepatitis C RNA positive requiring treatment.
研究者
相似试验
已完成
2 期
A phase II, double blind, randomised, dose ranging, safety and efficacy trial of rapid intravenous infusion of Zoledronate versus Aredia in breast cancer patients with osteolytic metastasesCancerBreast cancerISRCTN29188871Cancer Research UK (CRUK) (UK)
未知
2 期
A phase 2, randomized, double-blind, dose finding study of DS-8500a in Japanese patients with type 2 diabetes mellitusType 2 Diabetes MellitusJPRN-jRCT2080223014DAIICHISANKYO Co.,Ltd.335
进行中（未招募）
1 期
A Phase 2a, dose-finding, randomized, double-blinded, placebo-controlled study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Efavirenz in Patients with Early Alzheimer’s DiseaseAlzheimer's DiseaseCTIS2023-509613-37-01Amsterdam UMC40
进行中（未招募）
1 期
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyType 1 DiabetesEUCTR2020-001317-20-LTImcyse SA84
进行中（未招募）
1 期
IMCY-0098 Proof of ACtion in Type 1 Diabetes - IMPACT StudyMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 DiabetesEUCTR2020-001317-20-BEImcyse SA84